Portage Biotech Inc. (NASDAQ:PRTG) Short Interest Update

Portage Biotech Inc. (NASDAQ:PRTG) was the recipient of a large decrease in short interest in March. As of March 15th, there was short interest totalling 13,800 shares, a decrease of 20.7% from the February 28th total of 17,400 shares. Currently, 8.4% of the shares of the company are short sold. Based on an average daily volume of 86,500 shares, the short-interest ratio is presently 0.2 days.

Hedge Funds Weigh In On Portage Biotech

An institutional investor recently bought a new position in Portage Biotech stock. Virtu Financial LLC purchased a new position in Portage Biotech Inc. (NASDAQ:PRTG) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 10,919 shares of the company’s stock, valued at approximately $73,000. Virtu Financial LLC owned 1.04% of Portage Biotech as of its most recent filing with the Securities and Exchange Commission (SEC). 13.36% of the stock is owned by institutional investors.

Portage Biotech Stock Performance

Shares of NASDAQ PRTG traded down $1.28 during midday trading on Wednesday, reaching $6.98. The company’s stock had a trading volume of 161,843 shares, compared to its average volume of 771,863. The company has a market cap of $7.32 million, a P/E ratio of -0.17 and a beta of 1.29. The business’s 50 day moving average price is $4.70 and its two-hundred day moving average price is $5.12. Portage Biotech has a fifty-two week low of $2.10 and a fifty-two week high of $23.01.

About Portage Biotech

Portage Biotech Inc, a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline includes PORT-2 for treatment of refractory NSCLC, melanoma, and refractory melanoma that is in phase I and phase II clinical trials; PORT-3, for treatment of solid tumors, which is in phase I clinical trials; PORT-6, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ia clinical trials; PORT-7, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ib clinical trials; PORT-1, an intratumoral amphiphilic solutions for treatment of advanced soft tissue sarcoma, which is in phase 3 clinical trials; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors that is in preclinical trials.